Renaissance Technologies's JAZZ Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 836,774 shares of Jazz Pharmaceuticals plc (JAZZ) worth $142.25 M, representing 0.22% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 48 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in JAZZ, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2019, adding 842,900 shares. Largest reduction occurred in Q1 2021, reducing 436,400 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Jazz Pharmaceuticals plc (JAZZ) Holding Value Over Time
Track share changes against reported price movement
Quarterly Jazz Pharmaceuticals plc (JAZZ) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -88,100 | Reduce 9.53% | 836,774 | $170.00 |
| Q3 2025 | +24,506 | Add 2.72% | 924,874 | $131.80 |
| Q2 2025 | -144,206 | Reduce 13.81% | 900,368 | $106.12 |
| Q1 2025 | +42,700 | Add 4.26% | 1.04 M | $124.15 |
| Q4 2024 | -48,100 | Reduce 4.58% | 1 M | $123.15 |
| Q3 2024 | +24,106 | Add 2.35% | 1.05 M | $111.41 |
| Q2 2024 | -139,700 | Reduce 11.99% | 1.03 M | $106.73 |
| Q1 2024 | -66,006 | Reduce 5.36% | 1.17 M | $120.42 |
| Q4 2023 | -76,041 | Reduce 5.82% | 1.23 M | $123.00 |
| Q3 2023 | +17,506 | Add 1.36% | 1.31 M | $129.44 |
| Q2 2023 | +35,500 | Add 2.83% | 1.29 M | $0.12 |
| Q1 2023 | -35,406 | Reduce 2.74% | 1.25 M | $0.15 |
| Q4 2022 | -8,494 | Reduce 0.65% | 1.29 M | $0.16 |
| Q3 2022 | -127,600 | Reduce 8.95% | 1.3 M | $133.29 |
| Q2 2022 | -91,200 | Reduce 6.01% | 1.43 M | $156.01 |
| Q1 2022 | -183,200 | Reduce 10.77% | 1.52 M | $155.67 |
| Q4 2021 | -298,500 | Reduce 14.93% | 1.7 M | $127.40 |
| Q3 2021 | -318,231 | Reduce 13.73% | 2 M | $130.21 |
| Q2 2021 | -345,410 | Reduce 12.97% | 2.32 M | $177.64 |
| Q1 2021 | -436,400 | Reduce 14.08% | 2.66 M | $164.37 |
| Q4 2020 | -235,900 | Reduce 7.07% | 3.1 M | $165.05 |
| Q3 2020 | -143,263 | Reduce 4.12% | 3.33 M | $142.59 |
| Q2 2020 | +39,663 | Add 1.15% | 3.48 M | $110.34 |
| Q1 2020 | -110,821 | Reduce 3.12% | 3.44 M | $99.74 |
| Q4 2019 | +431,670 | Add 13.85% | 3.55 M | $149.28 |
| Q3 2019 | +561,900 | Add 21.99% | 3.12 M | $128.14 |
| Q2 2019 | +562,700 | Add 28.23% | 2.56 M | $142.56 |
| Q1 2019 | +842,900 | Add 73.28% | 1.99 M | $142.95 |
| Q4 2018 | +254,407 | Add 28.40% | 1.15 M | $123.96 |
| Q3 2018 | +62,994 | Add 7.56% | 895,794 | $168.13 |
| Q2 2018 | -125,600 | Reduce 13.11% | 832,800 | $172.30 |
| Q1 2018 | -286,400 | Reduce 23.01% | 958,400 | $150.99 |
| Q4 2017 | +28,700 | Add 2.36% | 1.24 M | $134.65 |
| Q3 2017 | +14,600 | Add 1.22% | 1.22 M | $146.25 |
| Q2 2017 | +40,537 | Add 3.49% | 1.2 M | $155.50 |
| Q1 2017 | -399,337 | Reduce 25.59% | 1.16 M | $145.13 |
| Q4 2016 | +645,500 | Add 70.56% | 1.56 M | $109.03 |
| Q3 2016 | +195,292 | Add 27.14% | 914,800 | $121.48 |
| Q2 2016 | +504,408 | Add 234.50% | 719,508 | $141.31 |
| Q1 2016 | +196,300 | Add 1044.15% | 215,100 | $130.55 |
| Q4 2015 | -105,500 | Reduce 84.88% | 18,800 | $140.59 |
| Q3 2015 | +106,000 | Add 579.23% | 124,300 | $132.81 |
| Q2 2015 | +18,300 | New Buy | 18,300 | $176.07 |
| Q3 2014 | -11,200 | Sold Out | 0 | $0.00 |
| Q2 2014 | -43,593 | Reduce 79.56% | 11,200 | $147.05 |
| Q1 2014 | +54,793 | New Buy | 54,793 | $138.69 |
| Q3 2013 | -146,800 | Sold Out | 0 | $0.00 |
| Q2 2013 | +146,800 | Add 0.00% | 146,800 | $68.73 |
Renaissance Technologies's Jazz Pharmaceuticals plc Investment FAQs
Renaissance Technologies first purchased Jazz Pharmaceuticals plc (JAZZ) in Q2 2013, acquiring 146,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Jazz Pharmaceuticals plc (JAZZ) for 48 quarters since Q2 2013.
Renaissance Technologies's largest addition to Jazz Pharmaceuticals plc (JAZZ) was in Q1 2019, adding 1,993,101 shares worth $284.91 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 836,774 shares of Jazz Pharmaceuticals plc (JAZZ), valued at approximately $142.25 M.
As of the Q4 2025 filing, Jazz Pharmaceuticals plc (JAZZ) represents approximately 0.22% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Jazz Pharmaceuticals plc (JAZZ) was 3,549,371 shares, as reported at the end of Q4 2019.